PriceTargets.com logo

Organon & Co. - OGN Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $8.38
  • Forecasted Upside: 2.70%
  • Number of Analysts: 7
  • Breakdown:
  • 5 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$8.16 As of 02/2/2026 12:22 PM ET
▼ -0.385 (-4.51%)

This chart shows the closing price for OGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Organon & Co. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGN

Analyst Price Target is $8.38
▲ +2.70% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Organon & Co. in the last 3 months. The average price target is $8.38, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 2.70% upside from the last price of $8.16.

This chart shows the closing price for OGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 7 contributing investment analysts is to reduce stock in Organon & Co.. This rating has held steady since December 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/8/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/7/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/5/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
11/3/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 4 sell ratings
Ratings as of
1/2/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 5 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 5 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/29/2026Zacks ResearchDowngradeHold ➝ Strong Sell
12/9/2025BarclaysInitiated CoverageUnderweight$7.50
12/8/2025BarclaysUpgradeStrong Sell
11/11/2025JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$14.00 ➝ $12.00
11/11/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$10.00 ➝ $9.00
10/27/2025Piper SandlerDowngradeOverweight ➝ Underweight$5.00
10/8/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
9/27/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
5/22/2025BNP Paribas ExaneUpgradeStrong-Buy
5/15/2025Piper SandlerLower TargetOverweight ➝ Overweight$24.00 ➝ $18.00
5/5/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.00
5/2/2025Evercore ISIDowngradeOutperform ➝ Inline
4/9/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.00
2/14/2025BarclaysLower TargetOverweight ➝ Overweight$26.00 ➝ $24.00
2/14/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00
1/15/2025TD CowenUpgradeHold
9/18/2024Evercore ISIUpgradeStrong-Buy
9/6/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$18.00 ➝ $20.00
5/3/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$18.00 ➝ $20.00
4/29/2024Piper SandlerBoost TargetOverweight ➝ Overweight$22.00 ➝ $24.00
2/20/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$16.00 ➝ $18.00
11/22/2023Piper SandlerLower TargetOverweight ➝ Overweight$32.00 ➝ $22.00
11/3/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$33.00 ➝ $16.00
10/25/2023Piper SandlerLower TargetOverweight ➝ Overweight$33.00 ➝ $32.00
10/12/2023Bank of AmericaLower Target$23.00 ➝ $19.00
10/11/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$27.00 ➝ $22.00
9/21/2023BarclaysInitiated CoverageOverweight$28.00
8/9/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$25.00 ➝ $27.00
3/15/2023Raymond James FinancialInitiated CoverageOutperform$33.00
11/4/2022Morgan StanleyLower TargetEqual Weight$27.00 ➝ $24.00
10/14/2022Bank of AmericaDowngradeNeutral ➝ Underperform$25.00
10/12/2022Morgan StanleyLower TargetEqual Weight$35.00 ➝ $27.00
9/6/2022Piper SandlerUpgradeNeutral ➝ Overweight$37.00 ➝ $34.00
8/5/2022Bank of AmericaDowngradeBuy ➝ Neutral$40.00 ➝ $37.00
7/8/2022Morgan StanleyLower TargetEqual Weight$35.00 ➝ $34.00
4/27/2022The Goldman Sachs GroupInitiated CoverageBuy$40.00
4/6/2022Morgan StanleyLower TargetEqual Weight$37.00 ➝ $35.00
2/22/2022Morgan StanleyBoost TargetEqual Weight$35.00 ➝ $37.00
10/7/2021Piper SandlerInitiated CoverageNeutral$35.00
9/1/2021Bank of AmericaInitiated CoverageBuy$43.00
8/18/2021CitigroupBoost TargetBuy$35.00 ➝ $43.00
8/16/2021Morgan StanleyBoost TargetEqual Weight$33.00 ➝ $35.00
7/22/2021CitigroupInitiated CoverageBuy$35.00
6/15/2021JPMorgan Chase & Co.Initiated CoverageNeutral$38.00
6/11/2021Morgan StanleyInitiated CoverageEqual Weight$33.00
6/10/2021Evercore ISIInitiated CoverageOutperform
6/3/2021TD CowenInitiated CoverageMarket Perform$40.00
6/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$35.00
6/2/2021Truist FinancialInitiated CoverageBuy$48.00
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 102 positive mentions
  • 6 negative mentions
  • 6 very negative mentions
Mentions as of
7/7/2025
  • 18 very positive mentions
  • 109 positive mentions
  • 9 negative mentions
  • 6 very negative mentions
Mentions as of
8/6/2025
  • 17 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 23 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 17 very positive mentions
  • 8 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 25 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 12 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 12 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Organon & Co. logo
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Read More

Today's Range

Now: $8.16
Low: $8.15
High: $8.53

50 Day Range

MA: $7.80
Low: $6.83
High: $9.78

52 Week Range

Now: $8.16
Low: $6.18
High: $17.23

Volume

1,142,292 shs

Average Volume

6,472,569 shs

Market Capitalization

$2.12 billion

P/E Ratio

4.25

Dividend Yield

0.94%

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Organon & Co.?

The following Wall Street research analysts have issued research reports on Organon & Co. in the last twelve months: Barclays PLC, BNP Paribas Exane, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for OGN.

What is the current price target for Organon & Co.?

0 Wall Street analysts have set twelve-month price targets for Organon & Co. in the last year. Their average twelve-month price target is $8.38, suggesting a possible upside of 2.7%. JPMorgan Chase & Co. has the highest price target set, predicting OGN will reach $12.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $5.00 for Organon & Co. in the next year.
View the latest price targets for OGN.

What is the current consensus analyst rating for Organon & Co.?

Organon & Co. currently has 5 sell ratings, 1 hold rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for OGN.

What other companies compete with Organon & Co.?

Other companies that are similar to Organon & Co. include Abivax, Axsome Therapeutics, Arrowhead Pharmaceuticals, Krystal Biotech and Praxis Precision Medicines. Learn More about companies similar to Organon & Co..

How do I contact Organon & Co.'s investor relations team?

Organon & Co.'s physical mailing address is 2000 Galloping Hill Road, Kenilworth, New Jersey 07033. The company's listed phone number is 551-430-6900 and its investor relations email address is [email protected]. The official website for Organon & Co. is www.organon.com. Learn More about contacing Organon & Co. investor relations.